Jeffrey Williams
Optometrist · Riverhead, NYNPI 1396945143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 311 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 9.6% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,555, 2.4 times the $1,078 reported in 2019. Among optometrist clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $31.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$954
- Harrow Eye, LLC$822
- Dompe US, Inc.$771
- AbbVie$755
- Bausch & Lomb Americas Inc.$744
- Sun Pharmaceutical Industries Inc.$710
- plus $5K from 23 others
What the payments were for
- Consulting fees$2503%
- Speaking & faculty fees$1001%
- Food & beverage$9,54196%
- Education$180%
- Entertainment$220%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 44 | $954 |
| Harrow Eye, LLC | 16 | $822 |
| Dompe US, Inc. | 26 | $771 |
| AbbVie(2 entities) | 22 | $755 |
| Bausch & Lomb Americas Inc. | 36 | $744 |
| Sun Pharmaceutical Industries Inc. | 26 | $710 |
| LKC Technologies, Inc. | 4 | $656 |
| Alcon | 22 | $633 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $519 |
| Oyster Point Pharma, Inc. | 20 | $494 |
| Biohaven Pharmaceutical Holding Company Ltd. | 11 | $337 |
| Ocular Therapeutix, Inc. | 2 | $275 |
| Kala Pharmaceuticals, Inc. | 8 | $260 |
| Pfizer | 12 | $250 |
| Biohaven Pharmaceuticals, Inc. | 8 | $213 |
| Shire North American Group Inc | 6 | $207 |
| Tarsus Pharmaceuticals, Inc. | 7 | $189 |
| Aerie Pharmaceuticals, Inc. | 5 | $189 |
| Eyevance Pharmaceuticals LLC | 4 | $162 |
| Maculogix, Inc. | 5 | $141 |
| Glaukos Corporation | 1 | $124 |
| Rxsight Inc | 1 | $124 |
| Amgen | 1 | $122 |
| Coopervision Inc. | 4 | $109 |
| Johnson & Johnson Vision Care, Inc. | 2 | $42 |
| Sight Sciences, Inc. | 2 | $36 |
| Polynovo North America LLC | 1 | $35 |
| Visioneering Technologies, Inc. | 2 | $32 |
| Optos, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VEVYE$371
- DEXTENZA$275
- VUITY$256
- CEQUA$247
- XIIDRA$238
- LUMIGAN$144
- Oxervate$142
- Rhopressa$125
- Rocklatan$125
- MIEBO$125
- iStent inject W$124
- RXSIGHT CONTACT LENS$124
- RXSIGHT INJECTOR CARTRIDGE$124
- RXSIGHT INJECTOR HANDPIECE$124
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$124
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$124
- TEPEZZA$122
- EYSUVIS$118
- Zerviate$117
- TYRVAYA$117
How this compares
$9,931 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 110 | $6,115,630 |
| VevyeCyclosporine | 465 | $467,010 |
| XiidraLifitegrast | 311 | $379,058 |
| RestasisCyclosporine | 203 | $197,529 |
| CequaCyclosporine | 101 | $67,682 |
| VerkaziaCyclosporine | 36 | $63,571 |
| LumiganBimatoprost | 107 | $48,832 |
| XdemvyLotilaner | 18 | $31,526 |
| RocklatanNetarsudil Mesylat/Latanoprost | 63 | $29,356 |
| Cyclosporine | 57 | $25,319 |
| ZerviateCetirizine Hcl | 75 | $24,124 |
| RhopressaNetarsudil Mesylate | 57 | $19,211 |
| MieboPerfluorohexyloctane/Pf | 17 | $17,019 |
| VyzultaLatanoprostene Bunod | 44 | $16,280 |
| ZioptanTafluprost/Pf | 18 | $7,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $771 | $6,115,630110 claims |
| Harrow Eye, LLCVevye, Verkazia | $822 | $530,580501 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $744 | $412,357372 claims |
| AbbVieRestasis, Lumigan, Combigan | $755 | $250,402328 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $710 | $67,682101 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $189 | $48,567120 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $189 | $31,52618 claims |
| Eyevance Pharmaceuticals LLCZerviate | $162 | $24,12475 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBepreve, Loteprednol Etabonate | $519 | $8,09225 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $494 | $6,76711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,743 optometrist providers in New York.
Other optometrist in Riverhead
- Roy KlineLake Katrine$822K
- Susan ResnickNew York$463K
- Murray FingeretHewlett$374K
- Albert MorierSlingerlands$347K
- Denise WhittamNew York$343K
- Justin BazanBrooklyn$303K
- Jennifer TsaiNew York$275K
- Alexander KabiriQueens Village$268K
- Sophia VisanjiNew York$233K
- Jason ComptonNew York$181K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.